In a revolutionary step forward, Sheikh Shakhbout Medical City (SSMC), one of the United Arab Emirates' leading healthcare organizations, has unveiled a modern solution for individuals suffering from the debilitating effects of thyroid eye disease (TED). Sawing together SEHA and Mayo Clinic, SSMC has brought forth an FDA-endorsed pharmaceutical that stands to become a groundbreaking tool in the battle against this immune system ailment.
Thyroid eye disease, also known as Graves' orbitopathy or thyroid-associated orbitopathy, is a perturbing condition characterized by redness and enlargement of the muscles and adipose tissue located around the eyes. It's estimated to affect between 155 to 250 people per 100,000 of the population worldwide. The symptoms, which can range from mild to severe and even sight-threatening, include irritation, light sensitivity, gritty sensations, excessive tearing, eyelid swelling, redness, and pressure behind the eyes. In especially critical cases, it can result in double vision, bulging eyes (exophthalmos), and, unfortunately, even vision loss.
Besides the evident physical harm, TED may also have a heavy psychological effect on individuals, ruining their self-faith due to unavoidable changes in the look of their eyes.
The protagonist of this script is Teprotumumab-trbw, an antibody therapy that works by halting certain proteins in the body. The modern treatment offered at SSMC leads to a remarkable decrease in swelling, thereby resulting in enhanced sight, reduced discomfort, fewer flare-ups, and alleviation from double vision and protruding eyes.
The patient's encounter at SSMC highlights the transforming potential for this treatment. Upon his arrival at the medical facility, he presented with blurry vision, intense eye suffering, and unrelenting redness and weepiness in his eyes, which significantly hindered his day-to-day activities. Under the expert care of Dr. Habibullah Eatamadi, consultant oculoplastic and ophthalmic surgeon, and Dr. Ohood Almazrouie, oculoplastic and ophthalmic surgeon at SSMC, a thorough diagnosis of severe TED was confirmed.
After discussing treatment options, the patient decided to undergo therapy with the only FDA-approved medication for TED. Patients experienced remarkable improvement in their well-being and were able to carry out their daily activities, proving that the treatment had breathtaking results.
Dr. Eatamadi, mulling over this medical advancement, articulated his delight, expressing, "The presentation of this much-required medication to the locale offers people troubled with TED a powerful solution to their affliction.
By making therapy attainable at SSMC, we are striving to decrease the possibility of patients enduring long-term eyesight impairment. Furthermore, what renders this medicine distinct is its capability to address the root of the illness and not just its signs. Fight against TED is a major step forward with the implementation of this new measure making a brighter tomorrow possible.
An extensive TED program of care with contributions from ophthalmologists, neurologists, immunologists, ENTs, and physicians cements SSMC’s commitment to providing personalized and patient-centered care. Marlene Bezzani Moucarzel, the chief pharmacist at SSMC, emphasizes the importance of clinical pharmacists in improving healthcare systems. She added the commitment of the organization to providing safe and productive alternatives.
SSMC Chief Medical Officer, Dr. Matthew Gettman reaffirmed the center's strong commitment to healthcare saying, "Providing innovative solutions for our patients remains at the forefront of SSMC's priorities. We remain firmly committed to providing high-quality care and are constantly developing innovative new options for folks in our community and beyond."
Receiving the nod from the FDA, Sheikh Shakhbout Medical City is revolutionizing the existence of those dealing with Gladstone- lingering ophthalmopathy and corroborating its standing as a premier in the healthcare system of the United Arab Emirates, extending the horizons of healthcare for the gain of humanity.
(Rehash/Arpita Meher)
